Tenofovir Disoproxil Fumarate Tablets

This product is a nucleotide reverse transcriptase inhibitor that inhibits reverse transcriptase in a similar way to nucleoside reverse transcriptase inhibitors, thus having potential anti-HIV-1 activity. The active ingredient of this product, tenofovir bisphosphonate, can inhibit viral polymerase by directly competing with natural deoxyribose substrates and terminate the DNA chain by inserting into DNA. In vitro, this product can effectively fight against a variety of viruses, including those strains that are resistant to nucleoside reverse transcriptase inhibitors. In vitro, the IC50 of this product against wild-type HIV-1 is 1.6 micromolar, against HIV-2 is 4.9 micromolar, and against HBV is 1.1 micromolar.

Tenofovir disoproxil fumarate. Molecular formula: C19H30N5O10P·C4H4O4. Molecular weight: 635.52

This product is a film-coated tablet, which appears white or off-white after removing the coating.

HIV-1 infection: This product can be used with other antiretroviral drugs to treat HIV-1 infection in adults, but not with (combination emtricitabine/tenofovir preparation) or ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate preparation)

Oral administration, 300 mg each time, once a day, can be taken on an empty stomach or with food.

In both studies, nearly 1/3 of the patients in the FDA group experienced adverse reactions, but the incidence was similar to that in the control group. Common adverse reactions of FDA include: mild to moderate gastrointestinal discomfort (commonly diarrhea, nausea, vomiting and flatulence); hypophosphataseemia of the metabolic system (1% incidence), mild to moderate decrease in serum phosphate (12% in the FDA group at 24 weeks, 7% in the control group, and 15% in the FDA group at 58 weeks). There is a risk of lactic acidosis.

This drug is contraindicated in patients with a prior allergy to any of the ingredients in this drug.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Clinical trials of tenofovir disoproxil fumarate did not include enough subjects aged 65 years or older to determine whether their responses differed from those of younger subjects. In general, elderly patients should be cautious in choosing doses, keeping in mind that they have decreased liver, kidney, and heart function, and are at increased risk of concurrent diseases or being treated with other medications.

1. This product can interfere with the blood concentration of didanosine. Tenofovir should be taken 2 hours before or 1 hour after didanosine. 2. The combined use of didanosine and this product can increase the blood concentration of didanosine, increasing the risk of pancreatitis. 3. This product is excreted from the kidneys through glomerular filtration and tubular secretion. When used in combination with other drugs that are secreted and excreted through the tubular secretion, it can increase each other's plasma drug concentration. Drugs that reduce renal function can also increase the blood concentration of this product. 4. This product can be used in combination with lamivudine, indinavir, lopinavir, and ritonavir to reduce the blood concentration of these drugs.

Sealed, store in a dry place.

300 mg x 30 tablets

24 months

Anhui Biochem Bio-Pharmaceutical Co., Ltd.

• Founded in:

  2003-12-17

• Address:

  No. 30 Hongfeng Road, High-tech Development Zone, Hefei City, Anhui Province

• Tax NO.:

  91340100752990430A

• Registered Funds:

  70 million yuan

• Website:

  Log in to view

• Email:

  Log in to view